Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

The Effect of Blood Carboxyhemoglobin Levels on NF-kB, NRF2 and PGC-1α During Low-flow and Normal-flow Anesthesia

NCT07352826 · tracked via the Priya Life Science Turkey tracker
Sponsor
Ataturk Training and Research Hospital
Phase
Not applicable
Started
2026-02-20
Last updated
2026-01-20

Condition(s) studied

Anesthesia

Investigational drug(s) / intervention(s)

low-flow anasthesiaNormal akımlı anestezi

low-flow anasthesia: In Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1

Normal akımlı anestezi: In Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%) with desflurane adjusted to maintain MAC = 1..

Study summary

Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. However, the endogenous production of CO suggests that it may confer protective mechanisms to the host. These protective effects include inhibition of platelet activation, smooth muscle relaxation, vasoactive properties, anti-inflammatory and anti-apoptotic actions, and beneficial influences on neurotransmission. Despite its toxic potential, low-concentration endogenous CO may provide protection linked to the body's defense mechanisms. In this study, we aimed to investigate the anti-apoptotic effects of carbon monoxide at low concentrations. To this end, the relationships between COHb levels and plasma levels of NF-κB, NRF2, and PGC-1α were analyzed statistically.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: aged 18-70 years classified as ASA I scheduled for inhalational anesthesia lasting ≥2 hours Exclusion Criteria: Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease pregnant or breastfeeding women trauma patients those undergoing emergency surgery procedures lasting \<2 hours those receiving intraoperative blood transfusion smokers individuals who decline participation

Primary outcome measure(s)

  • Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia — 24 HOUR
    COHb concentrations
  • Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia — 24 HOUR
    NF-kB concentrations
  • Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi — 24 HOUR
    NRF2 concentrations
  • Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi — 24 HOUR
    PGC-1α concentrations

Trial sites (1)

FacilityCityRegionStatus
Veysel Erzurum Turkey (Türkiye) Recruiting

More Ataturk Training and Research Hospital trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07352826 on ClinicalTrials.gov ↗ ← All trials in Turkey